BridgeBio's Acoramidis Shows First-Ever Kidney-Protective Effects in ATTR-CM
Event summary
- Acoramidis demonstrated early and sustained kidney-protective effects in ATTR-CM patients, with a 15.5% reduction in UACR by Day 28 and a +2.47 mL/min/1.73m²/year improvement in eGFR slope through Month 30.
- The drug's profile resembles that of direct kidney-acting medications like ACE inhibitors, ARBs, and SGLT2 inhibitors, suggesting a mechanism independent of TTR stabilization.
- Participants with larger eGFR dips upon acoramidis initiation experienced a 58% lower risk of death or cardiovascular hospitalization in the first year.
- Acoramidis is approved as Attruby® by the U.S. FDA and BEYONTTRA® by the EMA for ATTR-CM treatment.
The big picture
BridgeBio's acoramidis represents a potential paradigm shift in ATTR-CM treatment, offering the first evidence of direct kidney protection in this patient population. The drug's mechanism, which appears independent of TTR stabilization, sets it apart from existing therapies and could redefine standards of care. As BridgeBio continues to expand its portfolio of genetic condition treatments, acoramidis' success could validate its decentralized, hub-and-spoke business model.
What we're watching
- Clinical Validation
- Whether the observed kidney-protective effects of acoramidis will translate into long-term survival benefits and reduced cardiovascular hospitalizations.
- Market Differentiation
- How BridgeBio positions acoramidis against existing ATTR-CM therapies, leveraging its unique cardiorenal benefits to capture market share.
- Regulatory Strategy
- The pace at which BridgeBio seeks to expand acoramidis' indications or gain additional regulatory approvals based on these new findings.